A double-blind comparison of niflumic acid with phenylbutazone, oxyphenylbutazone and placebo in the treatment of osteoarthrosis.
D000814:Aniline Compounds / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006615:Hip / Q000503:physiopathology; D006801:Humans; D007717:Knee / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy*; D010113:Oxyphenbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D000814:Aniline Compounds; D000893:Anti-Inflammatory Agents; D009539:Nicotinic Acids; D010919:Placebos; D010653:Phenylbutazone; D010113:Oxyphenbutazone